Zyversa Therapeutics

ZVSA · NASDAQ

$0.001+$0.0008 (+400.00%)TodayMarket closed · Oct 20, 3:02 PM ET

Prev close $0.0002

ZVSA analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Sep 25, 2024

Bull case

ZyVersa Therapeutics Inc. exhibits a promising outlook due to its innovative drug development platforms, particularly the Cholesterol Efflux Mediator™ VAR 200 and the monoclonal antibody inflammasome ASC inhibitor IC 100, which target chronic renal and inflammatory diseases with significant unmet medical needs. The recent $2.7 million cash influx from warrant exercises reflects strong investor interest and confidence in the company's clinical programs, with a noted increase in trading volume suggesting robust market activity. Additionally, the company has improved its probability of success for VAR 200 in treating diabetic kidney disease (DKD) to 25%, supported by strong preclinical data and the approval of a Phase 2a clinical trial protocol, indicating actionable progress in the company's therapeutic development pipeline.

Bear case

ZyVersa Therapeutics reported a significant net loss of $106.2 million for 2023, translating to a loss of $108.97 per share, which raises concerns about its financial viability. The company faces multiple risks, including potential clinical trial failures, challenges in securing regulatory approvals for its drug candidates VAR 200 and IC 100, and the possibility of limited commercial opportunities stemming from market size and competition. Additionally, issues such as insufficient funding, potential dilution from future equity financing, and the threat of delisting from Nasdaq cast further doubt on the company's outlook and operational stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.